Scorpion Therapeutics is a clinical-stage oncology company that builds selective small-molecule precision medicines using an integrated platform spanning cancer biology, medicinal chemistry, and data sciences. Its lead program is STX-478, an allosteric, mutant-selective PI3Kα inhibitor that entered a Phase 1/2 trial in 2023 and has progressed into multiple expansion cohorts across solid tumors and breast cancer as monotherapy and in combination. The company also advances a clinical-stage EGFR inhibitor franchise including STX-721 and STX-241, plus a discovery pipeline of next-generation precision oncology therapies. Scorpion plans to use the proceeds from the Series C to expand clinical development of STX-478 and continue advancing its clinical and discovery-stage programs. Management states the company is on-track to disclose initial safety, PK/PD, and preliminary efficacy data at a future academic conference. The financing strengthens Scorpion’s balance sheet to support rapid development of its pipeline. Scorpion Therapeutics has developed a drug-hunting engine that integrates translational medicine, chemical biology, medicinal chemistry, and data science to discover targeted cancer therapies. The company is building a pipeline in three tracks: best- or first-in-class candidates against known high-impact oncogenes; candidates against historically “undruggable” non-enzymatic targets; and a new wave of protein targets discovered by Scorpion. Proceeds from the financing will support continued development of the platform and advancement of multiple therapeutic candidates across varied biological approaches for tumor targeting. Scorpion plans to name its first development candidate in 2021 and initiate clinical trials in 2022. Since its founding in the first quarter of 2020, the company has raised approximately $270 million. Scorpion Therapeutics builds a drug discovery and development engine that integrates cancer genomics, medicinal chemistry, and translational medicine to create next-generation small-molecule oncology therapies. The company aims to deliver best- and first-in-class small molecules that are safe, well-tolerated, and provide deeper, more durable responses for patients with treatment-resistant or untreatable cancers. Scorpion’s initial strategy focuses on three efforts: designing best/first-in-class drugs against known oncogenes; drugging classically undruggable cancer targets; and discovering and rapidly drugging novel transformative targets. It was founded by a team of drug developers and cancer researchers including Gary D. Glick, Keith Flaherty, Gaddy Getz, and Liron Bar-Peled, and is led by an experienced scientific team including Darrin Stuart, Angel Guzman Perez, and Erica Jackson. The company closed a $108 million Series A financing to advance its “Precision Oncology 2.0” platform and preclinical pipeline. The financing will support its discovery engine, next-generation chemistry, and translational efforts to move programs toward clinical development.

Total raised

$420M

Funding rounds

3

Latest round

Series C

Latest activity

Jul 2024